PATIENTS
PATIENTS
Clinical Trials
Our clinical trials help to advance the understanding of innovative medicines and determine whether the new treatments being developed are safe and effective.
We know that the decision to participate in clinical trial research is not made lightly, and we sincerely thank all the patients and families who choose to participate. Your physician is the best person to help you decide if a clinical trial or any other treatment option is right for you.
The potential treatments listed below are currently under investigation. Their safety and effectiveness have not been established. An investigational drug must be proven safe and effective in clinical trials before it can be approved by the health authorities for prescription use or for use outside of an investigational research study.
Learn more about clinical trials and how they work.
About PROTAC Protein Degraders:
Proteins are molecules that carry out important processes in our cells. However, sometimes certain proteins become damaged or too abundant, which can lead to disease. One of the ways the body naturally targets and eliminates harmful proteins is through the ubiquitin-proteasome system, or UPS. Arvinas is developing a way to make use of this process to destroy disease-causing proteins, called PROTACs. PROTACs have the potential to make use of the body’s natural disposal system to break down proteins that cause different diseases and are currently being studied in clinical trials.
The agents listed below are currently under investigation. Their safety and effectiveness have not been established.
ARV-027 is an investigational oral, peripherally restricted PROTAC degrader designed to selectively target and eliminate toxic polyglutamine-expanded androgen receptor (polyQ-AR) in skeletal muscle. ARV-027 is currently undergoing a clinical trial in the Netherlands to determine how well it works and how safe it is for treating spinal-bulbar muscular atrophy (SBMA).
Currently Enrolling:
- A Study to Investigate ARV-027 in Healthy Male Participants and Participants with Spinal and Bulbar Muscular Atrophy (EUCT: 2025-523469-79-00). This is a study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of an investigational asset called ARV-027.
Please note that EUCT refers to the identifier for clinical trials in the EU accessible through the Clinical Trials Information Systems.
ARV-393 is an investigational oral medicine which is a PROTAC designed to specifically target and degrade a protein called B-cell lymphoma 6 (BCL6) that is present in many types of non-Hodgkin’s lymphomas and can become damaged or too abundant and promote the growth of certain types of cancer. ARV-393 is currently undergoing clinical trials to determine how well it works and how safe it is for treating non-Hodgkin’s lymphomas.
Currently Enrolling:
- A Phase 1 First-in-Human study of ARV-393 is being conducted on adult participants diagnosed with advanced Non-Hodgkin’s Lymphoma (NHL) (NCT06393738). This clinical trial aims to investigate the safety, and potential activity of the investigational drug ARV-393 in patients with advanced relapsed/refractory non-Hodgkin’s lymphoma.
If you are interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov by clicking on the trial links above or contact us at +1-475-345-3374 or via email at clinicaltrialsARV-393@arvinas.com.
Please note above that NCT refers to the National Clinical Trial number assigned by clinicaltrials.gov.
Resources
Cancer, neurodegenerative diseases, and neuromuscular disorders are devastating conditions that can have a profound impact on patients, caregivers, and families. Collectively, these diseases affect millions of people around the globe, highlighting the importance of patient communities and organizations that offer connection, support, and shared experiences.
There are many resources available to help navigate diagnosis and life with these diseases. However, if you’ve been diagnosed, your physician is the best person to guide your treatment and care.
